Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases.
Daneng Li, Christiana Crook, Vincent Chung...
https://pubmed.ncbi.nlm.nih.gov/39263892/Actively Recruiting
Led by City of Hope Medical Center · Updated on 2026-08-03
12
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the side effects and safety of pressurized intraperitoneal aerosolized chemotherapy PIPAC using nab-paclitaxel along with standard chemotherapy drugs gemcitabine and cisplatin in adults with biliary tract cancer that has spread to the lining of the abdomen peritoneal metastases. This phase I trial aims to find out if delivering nab-paclitaxel as a fine mist directly into the abdomen can improve drug distribution and reduce side effects compared to traditional methods. Participants receive gemcitabine and cisplatin intravenously on days 1 and 8 of each 21-day cycle, and nab-paclitaxel is given via PIPAC on day 3 during the 1st, 3rd, and 5th cycles. Treatment may continue for up to 8 cycles if the disease does not progress and side effects remain manageable. The PIPAC procedure involves a laparoscopic surgery to deliver aerosolized chemotherapy directly inside the abdomen using a nebulizer and high-pressure injector. Throughout the study, participants will undergo imaging scans, surgical evaluations, blood tests, and quality of life assessments at several points before, during, and after treatment. Researchers will monitor adverse events, surgical complications, overall survival, progression-free survival, symptom changes, and physical activity levels using questionnaires and a wrist pedometer. Follow-up visits occur 4 weeks after treatment completion and then every 3 months for continued evaluation of treatment effects and safety.
CONDITIONS
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | PIPAC (pressurized intraperitoneal aerosolized nab‑paclitaxel) plus IV gemcitabine and cisplatin | Standard systemic chemotherapy with gemcitabine‑cisplatin (± immunotherapy) |
|---|---|---|
| What it is | An investigational combination that adds pressurized intraperitoneal aerosolized nab‑paclitaxel (PIPAC) to standard IV gemcitabine and cisplatin chemotherapy in a single‑group trial for biliary tract cancer with peritoneal metastases | Standard treatment is systemic gemcitabine–cisplatin chemotherapy, with added immunotherapy where guideline‑indicated |
| Role in the trial | Single‑group investigational regimen evaluated in the trial | Not part of the study, shown only as clinical context |
| Primary intended use | Treatment of biliary tract cancer patients with peritoneal metastases using both local (PIPAC) and systemic chemotherapy | Systemic control of metastatic biliary tract cancer |
| How it is given | Intraperitoneal aerosolized nab‑paclitaxel delivered under pressure via laparoscopy alongside intravenous gemcitabine and cisplatin | Intravenous gemcitabine and cisplatin with possible addition of immunotherapy per guideline |
| Evidence status | Safety is being assessed in an early‑phase trial; clinical outcomes like response and survival are exploratory | Gemcitabine‑cisplatin (± immunotherapy) has proven efficacy and is guideline‑endorsed for advanced biliary tract cancer |
| Important risks | Potential risks include surgery‑related complications, intraperitoneal chemotherapy toxicity, and systemic chemo side effects | Known systemic chemotherapy toxicities such as hematologic suppression and organ‑specific effects |
| Important limitations | Single‑group early‑phase design without comparison arm; small sample size limits generalizability | Systemic therapy may have limited penetration into peritoneal metastases, prompting exploration of loco‑regional approaches |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 weeks
Participants receive gemcitabine and cisplatin intravenously on days 1 and 8 of each 21-day cycle, and nab-paclitaxel is given as a pressurized aerosol into the abdomen on day 3 of cycles 1, 3, and 5. Treatment may continue for up to 8 cycles if tolerated and no disease progression occurs.
Repeated visits every 21 days for up to 8 cycles
Duration - Up to 1 year
Participants are monitored after treatment completion with visits at 4 weeks and then every 3 months to assess safety, treatment effects, and overall health.
Visits at 4 weeks post-treatment and every 3 months thereafter
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Daneng Li, Christiana Crook, Vincent Chung...
https://pubmed.ncbi.nlm.nih.gov/39263892/City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor